U.S. Markets closed
  • S&P Futures

    3,701.75
    -7.25 (-0.20%)
     
  • Dow Futures

    29,624.00
    -45.00 (-0.15%)
     
  • Nasdaq Futures

    11,357.25
    -19.50 (-0.17%)
     
  • Russell 2000 Futures

    1,682.90
    -3.20 (-0.19%)
     
  • Crude Oil

    79.27
    +0.53 (+0.67%)
     
  • Gold

    1,651.90
    -3.70 (-0.22%)
     
  • Silver

    18.77
    -0.14 (-0.74%)
     
  • EUR/USD

    0.9703
    -0.0135 (-1.3681%)
     
  • 10-Yr Bond

    3.6970
    -0.0110 (-0.30%)
     
  • Vix

    29.92
    +2.57 (+9.40%)
     
  • GBP/USD

    1.0832
    -0.0422 (-3.7502%)
     
  • USD/JPY

    143.3190
    +0.9840 (+0.6913%)
     
  • BTC-USD

    18,843.50
    -63.81 (-0.34%)
     
  • CMC Crypto 200

    434.61
    -9.92 (-2.23%)
     
  • FTSE 100

    7,018.60
    -140.92 (-1.97%)
     
  • Nikkei 225

    27,153.83
    -159.27 (-0.58%)
     

FDA Gives Nod To Nasal Spray Migraine Treatment From Impel NeuroPharma; Stock Jumps

·1 min read
  • The FDA has approved Impel NeuroPharma Inc's (NASDAQ: IMPL) Trudhesa (dihydroergotamine mesylate) nasal spray for the acute treatment of migraine with or without aura in adults.

  • Using Impel's Precision Olfactory Delivery technology, Trudhesa gently delivers dihydroergotamine mesylate to the bloodstream through the vascular-rich upper nasal space.

  • The commercial launch of Trudhesa is planned for early October 2021.

  • In the STOP 301 study, 38% had pain freedom, 66% had pain relief, and 52% had freedom from their most bothersome migraine symptom two hours after their first dose of Trudhesa.

  • In July, Impel NeuroPharma closed a million debt facility with Oxford Finance LLC and Silicon Valley Bank.

  • Under the terms of the debt facility, the second tranche of $10 million is available upon the approval of Trudhesa.

  • Related content: Benzinga's Full FDA Calendar.

  • Price Action: IMPL stock traded higher at 50% at $34.68 during the premarket session on the last check Friday. Trading in IMPL shares was halted earlier.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.